RNA is the intermediate in the flow of biochemical information drug development, [6] [7] [8] though the safety of this approach is a concern. [9, 10] from genes to proteins (figure 1). Accordingly, intervention in the Ribonucleases also have potential therapeutic utility. [11] [12] [13] [14] [15] metabolism of RNA presents an opportunity for the development These proteins are efficient catalysts of RNA cleavage, acting of chemotherapeutic agents. [1] Since the 1980s, antisense oligoin effect as RNA depolymerases. [16] Much interest has focused nucleotides and ribozymes have been pursued as the basis for on homologs and variants of bovine pancreatic ribonuclease treatments of viral infections, inflammatory disorders, hematolog-(RNase A), which is renowned as a model system in protein ical diseases, and cancer. [2] [3] [4] In 1998, the phosphorothioate anbiochemistry. [17] RNase A itself is not cytotoxic. In contrast, tisense oligonucleotide fomivirsen was approved by the US FDA bovine seminal ribonuclease, which is a homodimer, is endowed for the treatment of cytomegalovirus retinitis in immunowith antitumoral, immunosuppressive, and antiviral activities. [18] compromised patients. [5] More recently, manipulation of the RNA Ranpirnase (which is also known as P-30 protein) is an amphibian interference machinery has garnered much interest as a basis for homolog that has marked toxicity for tumor cells, [19] and is the the P-O 5′ bond on the 3′ side of a pyrimidine nucleobase in an RNA strand.
The ribonucleolytic activity of ranpirnase is necessary for its cytotoxicity. A decrease in ribonucleolytic activity leads to a corresponding reduction in cytotoxicity. [24] Although ranpirnase assumes the kidney-shaped tertiary structure that is typical of the RNase A superfamily (figure 2) [30, 33] and has the key catalytic residues, its value of kcat/KM (which is the second-order rate constant and thus a measure of catalytic efficiency) is 10 4 -fold less than that of RNase A for cleavage of their best known substrates only ribonuclease to have been studied in a human clinical under similar conditions. [34] A low affinity for its substrate contribtrial. [20, 21] Here we review the structure and function of ranpirnase, utes to its low kcat/KM value. In addition, nuclear magnetic which has become the archetype of a new class of cancer chemoresonance spectroscopy and molecular dynamics simulations have therapeutic agent. [22] revealed that ranpirnase has an extremely rigid β-sheet, [35, 36] which could deter an 'induced fit' [37] necessary for substrate binding and 1. History of Ranpirnase turnover.
The substrate specificity of ranpirnase can be considered on In the early 1970s, Shogen and Yoan [23] discovered that extracts two levels. On the nucleobase level, ranpirnase prefers to cleave from embryos of the Northern Leopard frog (Rana pipiens) have the phosphodiester bond on the 5′ side of a guanine. This preferantitumoral activity. Nearly two decades later, Ardelt et al. [24] ence is in marked contrast to that of RNase A, which has little attributed that activity to a basic protein, ranpirnase (meaning, preference for guanine versus adenine at this position. In the cell, Rana pipiens ribonuclease), which belongs to the RNase A supertransfer RNA (tRNA) has been reported to be the main target for family.
[25] In oocytes, ranpirnase localizes with yolk proteins.
[26] It ranpirnase. [39] The cleavage of tRNA occurs at the guanosinehas been postulated that ranpirnase is synthesized in the liver of guanosine bond in the variable loop or D-arm.
[40] The revelation of female frogs in a seasonal manner, and then secreted into the blood the atomic structure of a ranpirnase-nucleic acid complex has and deposited in oocytes as they mature.
[27] There and in embryos, provided insight into the structural basis for this substrate specificranpirnase has been speculated to play a role in host defense. [26] ity. [38] Ranpirnase is both cytotoxic and cytostatic toward cultured A notable feature of ranpirnase is its extraordinary conformatumor cells and inhibits the growth of xenograft tumors in mitional stability. Ranpirnase has a Tm value of 87°C (which is the ce. [28, 29] Currently, ranpirnase in combination with doxorubicin is temperature at the midpoint of the thermal transition between in a confirmatory phase IIIb clinical trial for the treatment of folded and unfolded states and thus a measure of conformational unresectable malignant mesothelioma, a cancer associated with exposure to asbestos. [20, 21] Moreover, ranpirnase has been granted both orphan-drug and fast-track status by the FDA.
Biochemical Attributes of Ranpirnase
The amino acid sequence of ranpirnase was determined in 1991, [24] and its 3-dimensional structure was reported 3 years later.
[30] Ranpirnase is a relatively small enzyme, with a molecular formula of C520H810N142O155S9 and a molecular mass of 11 820 Da. The active site of ranpirnase contains the catalytic triad (His10, Lys31, and His97) that is characteristic of the RNase A superfamily. [31] Ranpirnase possesses two additional active-site residues: Lys9 and an N-terminal pyroglutamate residue, which is formed by the co-translational cyclization of the encoded glutamine residue in the endoplasmic reticulum. [32] Like other members of the RNase A superfamily, ranpirnase catalyzes the cleavage of Ribbon diagram of the 3-dimensional structure of a crystalline ranpirnase-nucleic acid (dAdUdGdA) complex (PDB entry 2I5S). [38] The Nand C-termini of the protein, and 3′-and 5′-termini of the nucleic acid, are noted explicitly. The image was created with the programs MOLSCRIPT (Avatar Software AB, Stockholm) and RASTER3D (D.J. Bacon and W.F. Anderson, http://skuld.bmsc.washington.edu/raster3d/raster3d.html). [33] stability) and resists degradation by various proteases. [41] The exceptional conformational stability of ranpirnase is largely because of its tethered C-terminus, created by a C-terminal halfcystine residue. [42] This synapomorphic C-terminal disulfide bond is conserved in amphibian ribonucleases but is absent from mammalian homologs. [31] The hydrogen-bond network at the N-terminus [41] and the absence of a cis-proline residue [43] also contribute to the conformational stability of the enzyme. This exceptional stability is critical for cytotoxicity. Variants of ranpirnase with reduced conformational stability have less cytotoxic activity. [41, 42] On the other hand, glycosylation of ranpirnase at its consensus Nlinked glycosylation site (Asn69-Val70-Thr71) increases both conformational stability and cytotoxic activity. [44] 
Mechanism of Ranpirnase-Mediated Cytotoxicity
Ranpirnase is an atypical biodrug in that it is administered extracellularly but acts intracellularly. To exert its antitumoral 3 . Putative mechanism of ranpirnase-mediated cytotoxicity. [45] Cationic and anionic biomolecules are depicted in blue and red, respectively. (a) Ranpirnase (blue) forms an extracellular equilibrium complex with cellsurface heparan sulfate (red); (b) ranpirnase is internalized by endocytosis, translocates to the cytosol, evades the ribonuclease inhibitor protein (red horseshoe), and degrades transfer RNA (tRNA; red line); and (c) tRNA degradation leads to apoptosis.
effect, ranpirnase must reach the cytosol and there cleave RNA substrates. The generally accepted mechanism of ranpirnase-mediranpirnase is a hyperstable, single-domain protein, which remains ated cytotoxicity is divided into two major stages (as depicted in intact during its endocytosis. The mechanism of ranpirnase trans- figure 3 ): (i) cytosolic internalization; and (ii) catalytic degradalocation could be related to that used by cationic peptides, such as tion of RNA. [45] residues 47-57 of the HIV-1 TAT protein and nonaarginine. [50] 3.1 Cytosolic Internalization 3.2 Degradation of Cellular RNA and Induction
The first step for the cytosolic internalization of ranpirnase is its of Apoptosis binding to the cell surface. The existence of low-and high-affinity ranpirnase receptors on the cell surface has been reported, [46] but Once in the cytosol, ranpirnase degrades cellular RNA. other findings contradict their existence.
[47] The cell surface is Ranpirnase is an unusual homolog of RNase A in that it seems to highly anionic due to the abundance of sulfate, phosphate, and evade completely the cytosolic ribonuclease inhibitor protein carboxylate groups of its carbohydrates and lipids. It is probable (RI). [51, 52] RI is a 50-kD protein present in every surveyed mammathat ranpirnase, which is a highly cationic protein with a calculated lian cell. RI is composed of 15 leucine-rich repeats, a motif that isoelectric point of >9.5, [24] binds to the cell surface through often participates in protein-protein interactions. [53] RI binds to favorable Coulombic interactions. certain members of the RNase A superfamily with femtomolar After binding to the cell surface, ranpirnase is internalized affinity, and renders them inactive. The complex formed by through energy-dependent endocytosis. The role of the GTPase human RI and human pancreatic ribonuclease is among the tightdynamin in this process is under investigation. [47, 48] Internalized est known in biology (Kd = 2.9 × 10 -16 mol/L). [54] The ability of ranpirnase is routed to endosomes. Drugs that disrupt retrograde ranpirnase to evade RI is likely to be necessary for its cytotoxic transport from the trans-Golgi network to the endoplasmic reticuactivity, as non-cytotoxic mammalian ribonucleases become lum potentiate the cytotoxicity of ranpirnase.
[ [47] [48] [49] These and other cytotoxic by incorporating residues that enable RI evasion. [54, 55] results suggest that the trans-Golgi network is an inefficient site Moreover, the cytotoxicity of variants correlates with their RIfor the translocation of ranpirnase, and that endosomes are a key evading ability. [56] compartment for cytotoxic delivery. In the cell, the ribonucleolytic activity of ranpirnase is directed The means by which ranpirnase, which is extremely hydrophilpredominantly towards tRNA, leaving ribosomal RNA (rRNA) ic, ultimately crosses a lipid bilayer is not understood. To facilitate and messenger RNA (mRNA) largely intact. [39] The basis for this successful entry into the cell, the diphtheria toxin and ricin prospecificity is not understood, though bound proteins could protect teins utilize a distinct translocation domain, which dissociates from a catalytic domain upon cytosolic entry. In contrast, rRNA and mRNA from ranpirnase cleavage. The susceptibility of non-coding RNA, such as microRNA or small-interfering RNA Ranpirnase has been administered as a single agent in two (siRNA), to ranpirnase cleavage is unknown.
phase I clinical studies to determine the optimal dose and schedule in patients with various solid tumors. [20, 75] These phase I studies Degradation of tRNA by ranpirnase inhibits protein synthesis indicated that ranpirnase is well tolerated. The maximum tolerated in the cell and leads to apoptosis. [57, 58] The cytotoxic effect of dose was 960 μg/m 2 , and the recommended dose for phase II ranpirnase becomes noticeable after a longer incubation (≈48 h, studies was 480 μg/m 2 /week. Ranpirnase has been evaluated in in vitro) than required for drugs that block translation, such as phase II clinical trials as a single agent in patients with non-smallcycloheximide (≈2 h). In addition, ranpirnase-induced apoptosis cell lung cancer, [76] breast cancer, [77] renal cell cancer, [78] and does not require the high level of translation inhibition observed malignant mesothelioma. [79] The largest phase II trial for with cycloheximide, suggesting that the inhibition of protein synranpirnase was in patients with malignant mesothelioma. Among thesis is not the sole cause of ranpirnase-induced apoptosis. [59] In 81 patients who were evaluated for tumor response, 41 patients HeLa cells, ranpirnase-induced cytotoxicity is initiated with the showed a decrease in tumor progression, which justified subseactivation of the stress-activated c-Jun N-terminal kinase (JNK), quent phase III studies on this tumor type. In the initial phase III followed by the activation of caspase-9, which activates the execustudies, 154 patients were treated with either ranpirnase (84 pationer caspase-3 and -7. Caspase-8 or the tumor-suppressor protein tients) or doxorubicin (70 patients). In these studies, ranpirnase p53 are not required in this pathway. [60] Other studies with the treatment provided markedly increased survival compared with HL-60 leukemic cell line implicate the activation of serine protedoxorubicin treatment. [20, 21] Reversible renal toxicity was the maases along with these caspases. [61] The induced apoptosis is enjor adverse effect. The current confirmatory phase IIIb study is an hanced by mild hyperthermia. [62] open-label, multicenter, and international study, with the goal of
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comparing the efficacy of ranpirnase plus doxorubicin versus doxorubicin alone. [20, 21] Ranpirnase is more toxic to tumor cells than to normal cells in vitro and in vivo. The mechanism for this selectivity is un-5. Engineering Ranpirnase and Future Directions known, but a promising hypothesis is that ranpirnase is selectively There have been attempts to endow ranpirnase with increased internalized by tumor cells. In general, tumor cells are more toxicity toward tumor cells. Nearly all non-Hodgkin lymphoma negatively charged than are homologous normal cells. [63, 64] Morecells display a specific cell-surface receptor, CD-22. A human over, the level of sialic acid-rich gangliosides is greater and the monoclonal antibody against CD-22 has been covalently linked to phospholipid content is altered in certain tumor cells. [65, 66] The ranpirnase. [80] This fusion protein was 10 4 -fold more toxic to nonelevated anionic character of tumor cells could promote their Hodgkin lymphoma cells than was wild-type ranpirnase because interaction with the highly cationic ranpirnase. Other viable hypoof increased binding to the tumor cells. In addition, this protein theses include a different and more efficient intracellular routing showed enhanced potency and specificity along with decreased of ranpirnase to the cytosol in tumor cells, and a greater susceptisystemic toxicity in mice. bility of rapidly growing tumor cells to RNA degradation.
The ribonucleolytic activity of ranpirnase is 10 4 -fold lower 4. Therapeutic Applications than that of other mammalian homologs. [34] Accordingly, it could be both possible and advantageous to engender ranpirnase with In vitro, ranpirnase has been shown to be cytotoxic/cytostatic to greater ribonucleolytic activity without compromising other attriba range of cell lines, including 9L rat glioma, [46] K-562 human utes required for its cytotoxicity, such as cationicity, RI evasion, leukemia, [34, 42] Colo 320 CM human colon adenocarcinoma, [28] and conformational stability. Either enhancing substrate binding HL-60 human leukemia, [67] LNCaP and JCA-1 human prostate or alleviating β-sheet rigidity could yield variants with increased cancer, [67] HT-29 human colorectal cancer, [68] and U937 human ribonucleolytic activity and, hence, greater chemotherapeutic effilymphoma cell lines.
[69] Typical 50%-inhibitory concentrations cacy. (IC 50 ) for the proliferation of 9L rat glioma [28, 46] and K-562 human leukemia cells [34] are near 10 -7 mol/L. Concomitant administration 6. Conclusions of ranpirnase with tamoxifen, [70, 71] cisplatin, [71] or vincristine [68] results in increased toxicity. In combination with vincristine, Ranpirnase is a cytotoxic ribonuclease that affords a novel ranpirnase has shown toxicity against multidrug-resistant tustrategy for cancer chemotherapy. Ranpirnase is internalized by mors. [68] In vivo, ranpirnase treatment has prolonged the survival tumor cells and degrades tRNA, which leads to the inhibition of of mice transplanted with human [68, 72] and murine tumors. [73, 74] protein synthesis and apoptosis. The cationicity and maintenance 
